Medplus Health Share Price

Medplus Health Services Limited is a mid‑cap company operating as one of India’s largest organised pharmacy retail chains, with a presence in both online and offline segments. Headquartered in Hyderabad, Telangana, the company was incorporated in 2008 and operates a network of retail pharmacy stores across multiple states, along with diagnostic services. The Medplus Health Services share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

Market sentiment around the Medplus Health Services stock price often mirrors shifts in pharmaceutical retail demand, store count growth, and investor views on the healthcare sector’s growth prospects. Factors such as the pace of network expansion, competitive intensity from other pharmacy chains, regulatory pricing mechanisms, and government policies on healthcare influence near‑term market valuation and medium‑term earnings forecasts. All these factors must be closely monitored to have an idea about the Medplus Health Services share price movements. 

The Medplus Health Services live share price provides real‑time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Medplus Health Services live price helps observe short‑term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the Medplus Health Services share price today helps investors understand real‑time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short‑term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. 

Medplus Health Services Limited Company Fundamentals 

A. Company Background

Medplus Health Services Limited was incorporated in 2008. The company’s registered office is located in Hyderabad, Telangana. Medplus Health Services is India’s second‑largest organised pharmacy retail chain, operating both online and offline pharmaceutical retailing, diagnostic services, and allied healthcare services. The company operates through segments: Retail, Diagnostics, and Others. The Retail segment focuses on the sale of pharmaceuticals and general items. The company has demonstrated impressive growth with a compound annual growth rate (CAGR) exceeding 20% in both sales and profits over the past five years. Medplus Health Services is listed on the Bombay Stock Exchange (BSE) under the scrip code 543427 and on the National Stock Exchange (NSE) under the symbol MEDPLUS. The company is focused on increasing its store generics (in‑house brand) contribution to 50‑60 per cent of revenues in the next two to three years. 

B. Product Lines 

• Pharmaceutical drugs (prescription and OTC) 

• General merchandise and wellness products 

• Private label (store generics) products 

• Diagnostic services 

• Healthcare and wellness consultations 

• Medical devices and equipment 

• Health supplements and nutraceuticals 

C. Company Revenue Model 

• Primary revenue from retail sale of pharmaceutical products through physical stores. 

• Volume‑driven revenue based on number of prescriptions fulfilled and customer footfalls. 

• Revenue from diagnostic services offered at select locations. 

• Margin contribution from private label (store generics) products. 

• Online sales revenue from e‑commerce platform and delivery services. 

• Expanding geographical footprint contributing to new customer acquisition and revenue streams. 

• Focus on increasing store count to drive higher retail sales. 

• Investment in diagnostic infrastructure to expand healthcare service offerings. 

• Seasonal variations in demand for wellness and seasonal medicines affecting revenue patterns. 

• Government policy changes and drug price regulation influencing revenue stability. 

D. Geographic Presence 

• Headquartered in Hyderabad, Telangana, India. 

• Strong presence across multiple states in India through retail pharmacy network. 

• Focus on expanding into new geographical areas and cities. 

• Online presence serving customers across India. 

• Operations concentrated in domestic healthcare retail market. 

E. Key Milestones 

• 2008: Incorporated as Medplus Health Services Limited. 

• Listed on the Bombay Stock Exchange and National Stock Exchange. 

• Became India’s second‑largest organised pharmacy retail chain. 

• Achieved CAGR exceeding 20% in both sales and profits over five years. 

• Expanding store generics (in‑house brand) contribution to revenues. 

F. Industry Perspective

Medplus Health Services operates in the retail pharmacy and healthcare industry. The Indian retail pharmacy market is projected to experience a robust CAGR of around 9% between 2020 and 2025, reaching a value of USD 36 billion by 2025. Notably, the penetration of organised pharmacy services has increased to around 20% by 2025, a significant increase from the 10% recorded in 2020. India’s healthcare sector is expected to reach USD 50 billion by 2030, driven by rising healthcare awareness and increased spending. The pharmaceutical market in India is the world’s 3rd largest by volume and 14th by value. Key drivers of demand include rising healthcare expenditure, increasing chronic disease prevalence, and government initiatives such as Ayushman Bharat. Challenges include pricing regulations, intense competition from unorganised players and other organised chains like Apollo Pharmacy, and regulatory compliance costs. 

Medplus Health Services Limited Stock Market Presence: Listings & Index Representation 

Medplus Health Services is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol MEDPLUS and on the Bombay Stock Exchange (BSE) with the scrip code 543427. Its listing on both exchanges ensures that the Medplus Health Services share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The ISIN for the company is INE804L01022. The company forms part of several benchmark indices that represent broad market segments. Medplus Health Services is included in indices such as Nifty 500, Nifty Smallcap 250, and Nifty Healthcare Index on the NSE. On the BSE, the company is a constituent of indices including BSE-100, BSE-200, BSE-500, BSE Healthcare, and S&P BSE AllCap. Being represented in multiple indices enhances the visibility and liquidity of the Medplus Health Services stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross-sectional comparisons within India’s healthcare distribution landscape. 

Medplus Health Services Limited Stock Performance and Share Price History 

The performance and share price history of Medplus Health Services Limited are influenced by a complex mix of operational, regulatory, and macroeconomic factors. A primary driver is the company’s store expansion pace, as any increase in store count directly impacts revenue visibility and future growth projections, often leading to appreciation in the Medplus Health Services share price. Government policies regarding drug pricing and retail pharmacy licensing also play a critical role. For instance, when regulations around drug pricing are tightened, concerns about profitability emerge, putting pressure on the Medplus Health Services stock price. Conversely, favourable policy moves such as the expansion of healthcare coverage have historically boosted investor sentiment. 

Another major factor is competition—from both organised pharmacy chains like Apollo Pharmacy and unorganised local chemists—which can alter long‑term growth projections and influence the Medplus Health Services share price. The company’s store expansion and same‑store sales growth directly impact revenue visibility. Quarterly financial results, especially net profit and store addition figures, cause immediate swings in the Medplus Health Services stock price. Additionally, broader market trends, crude oil‑linked logistics costs, geopolitical events affecting pharmaceutical supply chains, and even seasonal demand (e.g., flu season) contribute to volatility. Historically, the Medplus Health Services share price has shown resilience during health emergencies but has also faced declines during economic slowdowns. 

The 52‑week high of the stock is largely dictated by sentiment shifts and external shocks. When the company reports strong store additions and consistent revenue growth, the Medplus Health Services share price tends to rally toward its 52‑week high; conversely, any regulatory price cut or supply chain disruption can drive the Medplus Health Services share price down to a new low. The Medplus Health Services share price also hits its peak when management announces strong same‑store sales growth or expansion into new geographies, while a sharp spike in operational costs or intense competition pushes the Medplus Health Services share price toward the yearly bottom. Broader market sell‑offs, such as during economic uncertainty, often drag the Medplus Health Services share price to multi‑month lows, even if fundamentals are sound. Conversely, a bullish healthcare narrative or government health scheme expansion can lift the Medplus Health Services share price to a new 52‑week high. Additionally, quarterly earnings misses have historically pressured the Medplus Health Services share price to test its lowest levels in a given year. 

The Medplus Health Services share price has exhibited stable performance over the past year, shaped by the company’s leadership in India’s organised pharmacy retail sector. The Medplus Health Services share price recorded a positive total return over the last 1 year, outperforming broader market indices. The Medplus Health Services share price delivered a 5‑year CAGR exceeding 20% in both sales and profits, demonstrating strong long‑term wealth creation. The Medplus Health Services share price reached a 52‑week high of ₹1,045.30 and a 52‑week low of ₹732.00, indicating a trading range of approximately 30%. The Medplus Health Services share price recorded a strong rally in 2023, while the subsequent period has seen the Medplus Health Services share price consolidate near its highs. The Medplus Health Services share price has shown a 1‑month return that has been modest recently. 

The Medplus Health Services stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 43.3% jump in second‑quarter profit, driven by higher sales from new store openings and steady demand for its private label products, the Medplus Health Services stock price showed a positive reaction. The Medplus Health Services stock price has shown a pattern of strong positive momentum in years when the company’s earnings exceeded expectations, while periods of earnings moderation have contributed to consolidation in the Medplus Health Services stock price. Corporate developments, including strategic announcements such as the expansion into new geographic areas and the growth of private label products, have also influenced short‑term fluctuations in the Medplus Health Services share price. The Medplus Health Services share price has shown a 10‑year aggregate net profit that reflects the company’s sustained profitability. The Medplus Health Services share price reached its 52‑week high before consolidating, reflecting the stability of the organised pharmacy sector. The Medplus Health Services share price has shown a year‑to‑date return that has been modest, indicating stable performance. 

The Medplus Health Services share price has shown distinct seasonal patterns over the past decade. The best performing periods have been during expansions of healthcare coverage and during health‑related demand surges. In terms of annual performance, the Medplus Health Services share price delivered its strongest annual returns in 2021 and 2023. The stock has recorded positive annual returns in most recent years. The Medplus Health Services share price has demonstrated that the stock tends to perform better in periods of high healthcare spending and supportive government policies, while underperforming during phases of regulatory uncertainty and intense competition. 

Medplus Health Services Limited Investor Relevance and Role in Portfolio 

Medplus Health Services holds a significant position for portfolio investors who seek exposure to India’s healthcare sector with a focus on the retail pharmacy segment. The company’s leading position in organised pharmacy retail aligns it with investment strategies that value healthcare infrastructure and the formalisation of retail. The Medplus Health Services share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector‑specific funds monitor store count growth and healthcare spending indicators when evaluating allocation decisions. 

Institutional stakeholders play a significant role in Medplus Health Services’ ownership profile, with notable long‑term investment entities such as Nippon India Mutual Fund, Quant Mutual Fund, Kotak Mahindra Mutual Fund, and other institutional investors among key shareholders. Mutual fund holders of Medplus Health Services encompass those that seek healthcare and retail exposure, including Nippon India Pharma Fund, Quant Healthcare Fund, Kotak Small Cap Fund, and other fund houses. These investors represent a blend of domestic and institutional perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks. 

Based on data, Medplus Health Services exhibits varying levels of beta and volatility across different time horizons. Based on data, the long‑term beta of Medplus Health Services stands at 0.80‑1.00, indicating that the stock is generally less volatile or similarly volatile to the broader market over an extended period. Based on data, the weekly volatility has been reported as moderate and stable. Based on data, the beta coefficient from various sources ranges from 0.80 to 1.00. The Medplus Health Services stock price has shown periods of heightened responsiveness to sector‑specific news and quarterly earnings releases. The Medplus Health Services share price’s beta reflects that the company’s essential service nature and established infrastructure may provide some stability, though the healthcare retail sector remains sensitive to regulatory changes and drug price fluctuations. 

Medplus Health Services Limited Sectoral Relevance and Peer Positioning 

The sector relevance of Medplus Health Services is anchored in its role within the broader Indian organised pharmacy retail industry, where it competes with other retail pharmacy chains. As part of this industry, the company’s strategic positioning connects pharmaceutical manufacturers with end consumers through an organised retail network. Competitors in the organised pharmacy retail segment include companies such as Apollo Hospitals Enterprise Ltd (Apollo Pharmacy), Reliance Retail (Netmeds), Tata 1mg, and other regional and national pharmacy chains. Firms with parallels in either store count scale or customer reach are often referenced when evaluating relative performance and operational positioning within the sector. 

In valuation terms, factors like the Medplus Health Services P/E ratio have shown variations over different periods. The mean historical PE Ratio over the last five years stands at approximately 125.43, with the current PE Ratio at 49.78‑67.08, having changed significantly with respect to the historical average. Periods when investors perceived improvements in profitability or earnings sustainability have corresponded with expansion in valuation multiples, whereas phases of moderation in earnings momentum have seen valuation contraction. The Medplus Health Services P/E ratio decreased in 2024 and 2025 from its peak levels of 384x and 184x to its current level of around 50‑70x. 

Similarly, the Medplus Health Services EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from store network expansion and private label product growth supported directional improvement in earnings per share during favourable conditions. Medplus Health Services earnings have shown a trajectory that responded to both revenue growth and margin pressures over the analysed period. Medplus Health Services market cap has followed a pattern of strong growth followed by consolidation. 

Over years, the Medplus Health Services market cap has shown a strong increasing trend, reflecting investor confidence. The market cap increased from approximately ₹5,000 crore in 2021 to ₹8,000 crore in 2022, ₹9,500 crore in 2023, ₹10,000 crore in 2024, and reached a peak of over ₹10,500 crore in 2025. Subsequently, through the most recent period, the market cap has consolidated around ₹10,000-10,500 crore. This growth mirrors the appreciation in the Medplus Health Services share price and the broader performance of the healthcare sector. 

The Medplus Health Services earnings over the past ten years has been characterised by consistent growth. Net income showed a generally increasing trend, with reported net profit for FY 2024-25 reaching approximately ₹150-160 crore on revenue of ₹6,136 crore, representing a 9.09% growth over the previous year. The company has maintained a compound annual growth rate exceeding 20% in both sales and profits over the past five years. 

The Medplus Health Services EPS has shown an increasing trend over the majority of the past decade, indicating a strong financial track record. The diluted EPS has grown from under ₹5 per share in FY2021 to over ₹12.52 per share in the most recent period. Over a five‑year period, the company demonstrated consistent improvement in EPS, with average earnings per share growth exceeding 20% per year. 

The Medplus Health Services P/E ratio has shown fluctuations over the five‑year period. At the end of recent fiscal years, the P/E ratio varied, with 2021 at 384x, 2022 at 280x, 2023 at 225x, 2024 at 184x, and 2025 at 67x. The mean historical P/E ratio over the last five years is approximately 125x. The current P/E ratio stands at around 50-70x compared to the historical average, reflecting that investor expectations are adjusting to near‑term earnings growth. The Medplus Health Services share price has been influenced by these valuation metrics. The Medplus Health Services stock price continues to be evaluated in the context of its earnings potential and market position. 

Summary 

Medplus Health Services is a leading organised pharmacy retail chain in India listed on both the NSE and BSE, where the Medplus Health Services share price reflects healthcare demand cycles, store expansion progress, and regulatory policies. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare retail themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s pharmaceutical retail distribution market.